Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA Closes Financing Round


InteRNA Technologies said this week that it has secured an undisclosed amount of equity financing, which it said would be used to develop its preclinical microRNA-based melanoma treatment.

The drug candidate is a mimic of miR-3157, which has been shown in vitro to inhibit proliferation and induce apoptosis in tumor cells. Last year, InteRNA CEO Roel Schaapveld told Gene Silencing News that the company aims to move the agent into human testing by the end of 2013 (GSN 10/25/2012).

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.